[Therapeutic biomarkers of EGFR-TKI]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations show significant response to EGFR tyrosine kinase inhibitors (EGFR-TKI).
• EGFR exon 19 deletion and exon 21 L858R mutations are key indicators of sensitivity to EGFR-TKI therapy in NSCLC.
• Acquired resistance to EGFR-TKI therapy is a major challenge, limiting long-term patient outcomes.

Purpose of the Study:

• To review and summarize the known mechanisms of acquired resistance to EGFR-TKI in NSCLC.
• To highlight the importance of understanding resistance mechanisms for developing novel therapeutic strategies.
• To discuss potential therapeutic biomarkers for overcoming EGFR-TKI resistance.

Main Methods:

• Literature review of recent advances in EGFR-TKI resistance mechanisms in NSCLC.
• Analysis of identified resistance pathways and molecular alterations.
• Synthesis of information on therapeutic biomarkers and targeted drug development.

Main Results:

• Several acquired resistance mechanisms have been identified, including EGFR exon 20 T790M mutation, MET amplification, HGF expression, PTEN downregulation, FAS-NF-κB pathway activation, epithelial-mesenchymal transition, and small cell lung cancer transformation.
• These mechanisms contribute to the ineffectiveness of initial EGFR-TKI treatments over time.
• Understanding these diverse resistance pathways is crucial for predicting treatment response and failure.

Conclusions:

• Acquired resistance to EGFR-TKI is a complex, multi-faceted issue in NSCLC treatment.
• Further research into novel resistance mechanisms and the development of drugs to overcome them are essential for improving patient outcomes.
• Targeting EGFR effectively in NSCLC requires a comprehensive approach that addresses resistance pathways.